Alk7 and myostatin inhibitors and uses thereof

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 38/17 (2006.01) A61P 21/06 (2006.01)

Patent

CA 2558478

The invention relates to ALK7 soluble receptors and their uses as antagonists of the function of certain ligands such as GDF-8 (Myostatin) and GDF- 11. The ALK7 soluble receptor of the invention is useful as antagonists of GDF-8 and GDF-11 in the treatment of neuronal diseases or conditions such as stroke, spinal cord injury, and all peripheral nerve diseases. The ALK7 soluble receptor of the invention is also useful as GH (growth hormone) equivalent, and for increasing muscle mass.

L'invention concerne des récepteurs soluble d'ALK7 et leurs utilisations comme antagonistes de la fonction de certains ligands, tels que GDF-8 (myostatine) et GDF- 11. Le récepteur soluble d'ALK7 de l'invention est utile comme antagoniste de GDF-8 et de GDF-11 dans le traitement de maladies ou affections neuronales, telles que l'accident vasculaire cérébral, le traumatisme médullaire, et toutes les maladies du nerf périphérique. Le récepteur soluble d'ALK7 de l'invention est également utile comme équivalent de l'hormone de croissance, ainsi que pour augmenter la masse musculaire.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Alk7 and myostatin inhibitors and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Alk7 and myostatin inhibitors and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Alk7 and myostatin inhibitors and uses thereof will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1660815

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.